BACKGROUND: Abnormalities of mineral metabolism and inflammation may affect the cardiovascular system. We have assessed the relationship of left ventricular hypertrophy (LVH) with inflammation and mineral metabolism. METHODS: LVH was measured in 146 outpatients with stable coronary artery disease (SCAD) using echocardiography. Calcidiol (a vitamin D metabolite), parathyroid hormone (PTH), fibroblast growth factor-23, high-sensitivity C-reactive protein, MCP-1 (monocyte chemoattractant protein-1), galectin-3, NGAL (neutrophil gelatinase-associated lipocalin), and sTWEAK (soluble TNF-related weak inducer of apoptosis) plasma levels were studied. RESULTS: LVH, defined as septal thickness ≥11 mm, was present in 19.9% of cases. These patients were older [75.0 (61.0-81.0) vs 64.0 (51.0-76.0) years; p=0.002], had higher prevalence of left ventricular ejection fraction (LVEF)>40%, and had higher PTH [84.7 (59.6-104.7) vs 63.2 (49.2-85.2) pg/ml; p=0.007], galectin-3 [9.6 (8.0-11.1) vs 8.3 (6.9-9.9) ng/ml; p=0.037], and NGAL (208.5±87.6 vs 173.9±73.4 ng/ml; p=0.031) plasma levels than those without LVH. Glomerular filtration rate was lower in patients with LVH than in those without it (65.1±20.0 vs 74.7±19.9 mL/min/1.73 m2; p=0.021). There were no significant differences in hypertension (79.3 vs 68.4%; p=0.363) or sex between both groups. Variables showing differences based on univariate analysis and hypertension were entered into a logistic regression analysis. Only age [odds ratio (OR) =1.052 (1.011-1.096); p=0.013], PTH plasma levels [OR=1.017 (1.003-1.031); p=0.021], and LVEF>40% [OR=7.595 (1.463-39.429); p=0.016] were independent predictors of LVH. CONCLUSIONS: In patients with SCAD, elevated PTH levels are independently associated with the presence of LVH. Further studies are needed to elucidate the role of PTH in the development of myocardial hypertrophy.
BACKGROUND:Abnormalities of mineral metabolism and inflammation may affect the cardiovascular system. We have assessed the relationship of left ventricular hypertrophy (LVH) with inflammation and mineral metabolism. METHODS: LVH was measured in 146 outpatients with stable coronary artery disease (SCAD) using echocardiography. Calcidiol (a vitamin D metabolite), parathyroid hormone (PTH), fibroblast growth factor-23, high-sensitivity C-reactive protein, MCP-1 (monocyte chemoattractant protein-1), galectin-3, NGAL (neutrophil gelatinase-associated lipocalin), and sTWEAK (soluble TNF-related weak inducer of apoptosis) plasma levels were studied. RESULTS: LVH, defined as septal thickness ≥11 mm, was present in 19.9% of cases. These patients were older [75.0 (61.0-81.0) vs 64.0 (51.0-76.0) years; p=0.002], had higher prevalence of left ventricular ejection fraction (LVEF)>40%, and had higher PTH [84.7 (59.6-104.7) vs 63.2 (49.2-85.2) pg/ml; p=0.007], galectin-3 [9.6 (8.0-11.1) vs 8.3 (6.9-9.9) ng/ml; p=0.037], and NGAL (208.5±87.6 vs 173.9±73.4 ng/ml; p=0.031) plasma levels than those without LVH. Glomerular filtration rate was lower in patients with LVH than in those without it (65.1±20.0 vs 74.7±19.9 mL/min/1.73 m2; p=0.021). There were no significant differences in hypertension (79.3 vs 68.4%; p=0.363) or sex between both groups. Variables showing differences based on univariate analysis and hypertension were entered into a logistic regression analysis. Only age [odds ratio (OR) =1.052 (1.011-1.096); p=0.013], PTH plasma levels [OR=1.017 (1.003-1.031); p=0.021], and LVEF>40% [OR=7.595 (1.463-39.429); p=0.016] were independent predictors of LVH. CONCLUSIONS: In patients with SCAD, elevated PTH levels are independently associated with the presence of LVH. Further studies are needed to elucidate the role of PTH in the development of myocardial hypertrophy.
Authors: Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein Journal: Am Heart J Date: 2011-08 Impact factor: 4.749
Authors: Anna Jovanovich; Joachim H Ix; John Gottdiener; Kim McFann; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Mark Sarnak; Michael G Shlipak; Kenneth J Mukamal; David Siscovick; Michel Chonchol Journal: Atherosclerosis Date: 2013-09-13 Impact factor: 5.162
Authors: Raghava S Velagaleti; Philimon Gona; Daniel Levy; Jayashri Aragam; Martin G Larson; Geoffrey H Tofler; Wolfgang Lieb; Thomas J Wang; Emelia J Benjamin; Ramachandran S Vasan Journal: Circulation Date: 2008-11-10 Impact factor: 29.690
Authors: Natalia Carrillo-López; Laura Martínez-Arias; Jorge B Cannata-Andía; Manuel Naves-Díaz; Sara Panizo; Sara Fernández-Villabrille; María Piedad Ruiz-Torres; Adriana Dusso Journal: Calcif Tissue Int Date: 2021-02-13 Impact factor: 4.333
Authors: Renee Margossian; Paige L Williams; Wendy Yu; Denise L Jacobson; Mitchell E Geffner; Linda A DiMeglio; Russell B Van Dyke; Stephen A Spector; Gertrud U Schuster; Charles B Stephensen; Tracie L Miller; Steven E Lipshultz Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Juan Martínez-Milla; Álvaro Aceña; Ana Pello; Marta López-Castillo; Hans Paul Gaebelt; Óscar González-Lorenzo; Nieves Tarín; Carmen Cristóbal; Luis M Blanco-Colio; José Luis Martín-Ventura; Ana Huelmos; Andrea Kallmeyer; Joaquín Alonso; Carlos Gutiérrez-Landaluce; Lorenzo López Bescós; Jesús Egido; Ignacio Mahíllo-Fernández; Óscar Lorenzo; María Luisa González-Casaus; José Tuñón Journal: J Clin Med Date: 2022-07-17 Impact factor: 4.964
Authors: José Tuñón; Ignacio González-Hernández; Lucía Llanos-Jiménez; Joaquín Alonso-Martín; Juan M Escudier-Villa; Nieves Tarín; Carmen Cristóbal; Petra Sanz; Ana M Pello; Álvaro Aceña; Rocío Carda; Miguel Orejas; Marta Tomás; Paula Beltrán; Marta Calero Rueda; Esther Marcos; José María Serrano-Antolín; Carlos Gutiérrez-Landaluce; Rosa Jiménez; Jorge Cabezudo; Alejandro Curcio; Germán Peces-Barba; Emilio González-Parra; Raquel Muñoz-Siscart; María Luisa González-Casaus; Antonio Lorenzo; Ana Huelmos; Javier Goicolea; Borja Ibáñez; Gonzalo Hernández; Luis M Alonso-Pulpón; Jerónimo Farré; Óscar Lorenzo; Ignacio Mahíllo-Fernández; Jesús Egido Journal: BMJ Open Date: 2016-08-05 Impact factor: 2.692